Approved for use through 57/31/2005, OMB 0851-0031 U.S. Patow and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10715055	
	Filing Date		2003-11-17	
	First Named Inventor Geral		raid Cagle et al.	
	Art Unit		1618	
	Examiner Name Fay,		ay, Zohreh A.	
	Attorney Docket Numb	er	007109.00001	

CTATEMENT BY ADDITIONET			First Named Inventor Gerald			Gerald Cagle et al.				
			Art Unit	Art Unit			1618			
			Examiner Na	Examiner Name Fay, Zohreh A.						
					Attorney Doc	Attorney Docket Number 007			07109.00001	
	U.S.PATENTS									
	Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of of cited E		tee or Applicant ent	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

If you wish to add additional U.S. Patent citation information please click the Add button

	U.S.PATENT APPLICATION PUBLICATIONS							
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code4	Publication	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts	
	1								

If you wish to add additional Foreign Patent Document citation information please click the Add button

		NON-PATENT LITERATURE DOCUMENTS		ı
Examiner Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	T5	

1 Decision Rejecting Opposition, dated 10/30/2006 for EP 99 996 504.7	⊐
2 Provision of a copy of the minutes in accordance with Rule 78(4) EPC, dated 10/30/2006, for EP 99 956 504.7	ا ت

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant

See Kind Codes of USPTO Patient Documents at sever LISPTO_GOU(or MEPP 901.0.4. It East office that issued the document, by the shorter code (WPO) Standard ST3.3 For Justnesses patient concurrents, be indicated on the year of the represent must produce the serial number of the plotted requirement of the plotted countered.

**Indicated on the production of the production of the year of the plotted of the plotted on the plotted on the document under WIPO Standard ST1.6 if possible. **Applicant is to place a check mark here if Emploth inclusions the relation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10715055		
	Filing Date		2003-11-17		
	First Named Inventor Geral		d Cagle et al.		
	Art Unit Examiner Name Fay, 2		1618		
			Zohreh A.		
	Attorney Docket Numb	er	007109.00001		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
×	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement, See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was ofted in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.75(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) for the control of the contro

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

	Mal Hothadolott	>	
Signature	NOW SI SIOCHIEL	Date (YYYY-MM-DD)	2008-11-02
Name/Print	Dale H. Hoscheit	Registration Number	19090

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the tuBFPTO. Time will vary depending upon the individual case. Any comments on the amount of firm you require to complete this form and/or suggestions for medium public burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commence, P.O. 8bx 1445, Alexandric, N.2. 2315-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 14450, Alexandric, N.2. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is \$U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpuse for which the information is such by the U.S. Patient and Trademan Childre is to process and/or examine your submission resulted are a patient formation is used by the U.S. Patient and Trademan Childre is to process and/or examine your submission results are a patient formation or proceedings or the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant flow.
- 3. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuence of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public insepections or an insued platent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.